Skip to main content
. 2022 Mar 3;6(5):1525–1535. doi: 10.1182/bloodadvances.2021004319

Figure 1.

Figure 1.

Comorbidities in the study population. (A) Prevalence of each of the studied comorbidities in the MSKCC. (B) Co-incidence of pairs of comorbidities across the study cohort, as measured by Spearman’s correlation coefficient. Pairs with positive coefficients are in blue, and those with negative coefficients are in yellow. Comorbidities with >1 level (ie, moderate and severe pulmonary) are studied as a single comorbidity with ordinal levels. eGFR was measured using the CKD-EPI formula. IBD, inflammatory bowel disease.